stockrow
Friday 6 November 2026
Export LQDA’s income statement to Excel — free account
Liquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.
- Revenue
- +1,842.7%
- EPS
- +271.4%
- Free cash flow
- +270.2%
- Total debt
- −9.04%
Quarter to June 2026, against a year earlier
44.69
2.69
−5.68%
Follow LQDA
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 157.25 | 50.78 |
P/S ratio |
28.36 | 18.75 | 11.53 | 15.72 | |
P/FCF ratio |
0.00 | 0.00 | 80.72 | 47.03 | |
P/Operating CF |
(200.95) | 67.09 | 62.68 | 88.32 | |
P/B ratio |
89.03 | 66.33 | 30.59 | 36.32 | |
Price to Tangible BV |
129.49 | 78.33 | 32.63 | 37.62 | |
EV/Sales |
28.87 | 18.75 | 11.37 | 15.48 | |
EV/EBITDA |
0.00 | 0.00 | 69.52 | 40.99 | |
EV/Operating CF |
(19.83) | (83.19) | 68.28 | 41.61 | |
EV/FCF |
(19.15) | (74.18) | 79.63 | 46.31 | |
Quick Ratio |
1.88 | 1.80 | 1.98 | 2.07 | |
Current Ratio |
2.20 | 2.01 | 2.22 | 2.31 | |
Net Debt/EBITDA |
15.60 | 0.03 | (0.72) | (1.26) | |
Debt/Assets |
69.75% | 58.35% | 44.30% | 33.74% | |
Debt/Equity |
8.73 | 4.28 | 1.64 | 0.90 | |
Asset Turnover |
0.26 | 0.57 | 0.92 | 1.16 | |
Operating CF/Net income |
2.77 | 3.04 | 1.00 | 1.07 | |
Capex/Depreciation |
(1.91) | (6.37) | (5.69) | (28.09) | |
Interest Coverage |
0.25 | 2.87 | 9.47 | 13.58 | |
Research and Development Expense of Revenue |
17.20% | 18.41% | 9.46% | 10.01% | |
Selling, General and Administrative Expense of Revenue |
73.71% | 52.42% | 35.33% | 33.45% | |
Intangible Assets out of Total Assets |
0.03 | 0.02 | 0.02 | 0.01 | |
Share Based Compensation of Revenue |
14.53% | 7.83% | 6.94% | 6.04% | |
Graham Net Nets |
(0.01) | 0.00 | 0.01 | 0.02 | |
Graham Number |
0.00 | 0.00 | 2.58 | 8.81 | |
Earnings Yield |
(6.33%) | (2.35%) | 0.64% | 1.97% | |
Free Cash Flow Yield |
(5.31%) | (1.35%) | 1.24% | 2.13% | |
Revenue per Share |
0.63 | 1.07 | 1.51 | 1.93 | |
Operating CF per Share |
(0.11) | 0.51 | 0.60 | 0.90 | |
Capex per Share |
(0.01) | (0.02) | (0.03) | (0.13) | |
Free Cash Flow per Share |
(0.12) | 0.49 | 0.57 | 0.78 | |
Cash per Share |
1.82 | 2.22 | 2.53 | 3.20 | |
Shareholders Equity per Share |
0.26 | 0.52 | 1.23 | 2.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.26 | 0.52 | 1.23 | 2.20 | |
Free Cash Flow |
(10.68) | 42.21 | 50.16 | 69.01 | |
Working Capital |
123.78 | 137.63 | 183.32 | 248.41 | |
Capital Expenditures |
(0.91) | (2.04) | (2.83) | (11.23) | |
Net Current Asset Value |
(27.21) | (9.78) | 40.10 | 110.90 | |
EV/EBIT |
0.00 | 0.00 | 71.93 | 41.40 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 72.91 | 42.04 | |
| Other line items | |||||
Average Receivables |
20.08 | 28.41 | 37.70 | 59.28 | |
Average Payables |
4.16 | 4.18 | 9.83 | 12.05 | |
Average Inventory |
12.29 | 12.02 | 14.93 | 21.31 | |
Average Assets |
264.43 | 279.12 | 314.48 | 389.66 | |
Average Common Equity |
66.29 | 62.06 | 79.15 | 105.15 |
Columns are period end dates · fundamentals updated 26 Oct 2026